Cryo-Save

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2021 Financial Results

Retrieved on: 
Friday, July 16, 2021

OLDSMAR, Fla., July 15, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the Company), the worlds first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2021.

Key Points: 
  • OLDSMAR, Fla., July 15, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the Company), the worlds first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2021.
  • Consolidated revenues for the second quarter of fiscal 2021 were $7.21 million compared to $7.87 million for the second quarter of fiscal 2020, an 8% decrease.
  • The revenues for the second quarter of fiscal 2021 consisted of $7.16 million in processing and storage fee revenue and $46,000 in public banking revenue compared to $7.40 million in processing and storage fee revenue, $57,000 in product revenue, $214,000 in public banking revenue and $202,000 in license and royalty income for the second quarter of fiscal 2020.
  • More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with their babys cord blood and cord tissue stem cells.

StimLabs, LLC. Announces Launch of Second Umbilical Cord Derived Product: Corplex™ P

Retrieved on: 
Thursday, August 27, 2020

Corplex P, a shelf-stable Wharton's Jelly allograft obtained from donated human umbilical cord tissue, is intended for homologous use for the supplementation of connective tissue voids in open wound environments.

Key Points: 
  • Corplex P, a shelf-stable Wharton's Jelly allograft obtained from donated human umbilical cord tissue, is intended for homologous use for the supplementation of connective tissue voids in open wound environments.
  • Corplex P was born out of a growing and widespread demand for a conformable placental derived product.
  • Corplex, StimLabs' first umbilical cord product was launched in early Q1, and Corplex P, an umbilical cord derivative, is available today.
  • Corplex P is a Wharton's Jelly allograft obtained from donated human umbilical cord tissue.

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2020 Financial Results

Retrieved on: 
Friday, July 10, 2020

OLDSMAR, Fla., July 10, 2020 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the Company), the worlds first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2020.

Key Points: 
  • OLDSMAR, Fla., July 10, 2020 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the Company), the worlds first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2020.
  • Consolidated revenues for the second quarter of fiscal 2020 were $7.87 million compared to $8.13 million for the second quarter of fiscal 2019, a 3% decrease.
  • More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with their babys cord blood and cord tissue stem cells.
  • Besides being AABB accredited as a cord blood facility, Cryo-Cell was also the first U.S. (for private use only) cord blood bank to receive FACT accreditation for adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization.

Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2020 Financial Results

Retrieved on: 
Tuesday, April 14, 2020

OLDSMAR, Fla., April 14, 2020 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the Company), the worlds first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 29, 2020.

Key Points: 
  • OLDSMAR, Fla., April 14, 2020 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the Company), the worlds first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 29, 2020.
  • Consolidated revenues for the first quarter of fiscal 2020 were $7.62 million compared to $7.50 million for the first quarter of fiscal 2019, a 2% increase.
  • More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with their babys cord blood and cord tissue stem cells.
  • Besides being AABB accredited as a cord blood facility, Cryo-Cell was also the first U.S. (for private use only) cord blood bank to receive FACT accreditation for adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization.

Global Cord Blood Corporation to Report Second Quarter and First Half Fiscal 2020 Financial Results

Retrieved on: 
Thursday, November 21, 2019

HONG KONG, Nov. 21, 2019 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services,today announced that it plans to release unaudited financial results for the secondquarter and first half of fiscal year 2020 on Tuesday, November 26, 2019, after the market close.

Key Points: 
  • HONG KONG, Nov. 21, 2019 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services,today announced that it plans to release unaudited financial results for the secondquarter and first half of fiscal year 2020 on Tuesday, November 26, 2019, after the market close.
  • ET on Wednesday, November 27, 2019 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question and answer session.
  • Supplemental financial information referenced in the conference call and the secondquarter and first half of fiscal year 2020 earnings press release will be available at http://www.globalcordbloodcorp.com , in the section titled "Investor Center/Press Release", after 4:16 p.m.
  • Global Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood bankingoperator with multiplelicenses.Under current PRC government regulations, only one licensed cord blood bankingoperator is permitted to operate in each licensed region and no new licenses will be granted before 2020 in addition to the seven licenses authorized as of today.Global Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services.

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2019 Financial Results

Retrieved on: 
Tuesday, October 15, 2019

OLDSMAR, Fla., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the Company), the worlds first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2019.

Key Points: 
  • OLDSMAR, Fla., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the Company), the worlds first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2019.
  • Consolidated revenues for the third quarter of fiscal 2019 were $8.2 million compared to $7.9 million for the third quarter of fiscal 2018.
  • More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with their babys cord blood and cord tissue stem cells.
  • Besides being AABB accredited as a cord blood facility, Cryo-Cell was also the first U.S. (for private use only) cord blood bank to receive FACT accreditation for adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization.

Cord Blood Banking Market 2019 by Type of Bank, Application, End-use & Region to 2025: GMI

Retrieved on: 
Tuesday, August 6, 2019

Europe cord blood banking market is estimated to reach USD 7.6 billion by 2025.

Key Points: 
  • Europe cord blood banking market is estimated to reach USD 7.6 billion by 2025.
  • High growth is attributable to increasing efficient initiatives implemented by the European Union and various organizations will boost demand for cord blood banking.
  • Various offers and discounts provided by cord blood banks for long-term storage of cord blood cells will spur segmental growth.
  • Prominent industry players in cord blood banking market include Singapore Cord Blood Bank, CBR Systems, ViaCord LLC, Cordlife, FamiCord, Cryo-Save, Americord, Global Cord Blood Corporation, LifeCell and Jeevan Stem Cell Foundation.

Cord Blood Banking Market 2019 by Type of Bank, Application, End-use & Region to 2025: GMI

Retrieved on: 
Tuesday, August 6, 2019

Europe cord blood banking market is estimated to reach USD 7.6 billion by 2025.

Key Points: 
  • Europe cord blood banking market is estimated to reach USD 7.6 billion by 2025.
  • High growth is attributable to increasing efficient initiatives implemented by the European Union and various organizations will boost demand for cord blood banking.
  • Various offers and discounts provided by cord blood banks for long-term storage of cord blood cells will spur segmental growth.
  • Prominent industry players in cord blood banking market include Singapore Cord Blood Bank, CBR Systems, ViaCord LLC, Cordlife, FamiCord, Cryo-Save, Americord, Global Cord Blood Corporation, LifeCell and Jeevan Stem Cell Foundation.

Global Cord Blood Corporation to Report Second Quarter and First Half Fiscal 2019 Financial Results

Retrieved on: 
Tuesday, November 20, 2018

ET on November 28, 2018

Key Points: 
  • ET on November 28, 2018
    HONG KONG, Nov. 20, 2018 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release unaudited financial results for the second quarter and first half of fiscal year 2019 on Tuesday, November 27, 2018, after the market close.
  • ET on Wednesday, November 28, 2018 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question and answer session.
  • Supplemental financial information referenced in the conference call and the second quarter and first half of fiscal year 2019 earnings press release will be available at http://www.globalcordbloodcorp.com , in the section titled "Investor Center/Press Release", after 4:16 p.m.
  • Global Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses.